Analysts say Darzalex sales prognosis could be too cautious

Analysts from both US-based Jefferies and Danish bank Sydbank say that the sales forecast for Johnson & Johnson's drug Darzalex, which the company obtained through a licensing agreement with Genmab, is a tad too conservative, perhaps signaling a potential upgrade.

Photo: Tuala Hjarnø / Genmab / PR

The sales of Darzalex have exceeded expectations in the third quarter of the year, surpassing net sales expectations by more than DKK 850 million.

All taken together, Genmab's partner Janssen has achieved sales figures so big that Genmab's own estimate for the 2021 net sales might have been too cautious, say analysts from US-based Jefferies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs